Collaborators 

Eli Lilly & Company - strategic alliance to develop teplizumab and next generation CD3 molecules in type 1 diabetes and other autoimmune diseases.

Genzyme Corporation - Partnership to develop GMA161, an anti-CD16 Mab, and soluble Fc receptors.

Juvenile Diabetes Research Foundation (JDRF) - $2M grant to support clinical development of teplizumab in type 1 diabetes.

NIAID/NIH - Development of a novel and proprietary monoclonal antibody, MGAWN1, to treat West Nile virus infection.

NIAID/NIH - Development of a novel and proprietary antibody cocktail to be used as a post-exposure prophylaxis in respose to a smallpox outbreak or bioterrorist attack.

Utah State University - Development of a novel and proprietary West Nile Virus Mab for therapeutic treatment.

Washington University in St. Louis - Development of a novel and proprietary West Nile Virus Mab for therapeutic treatment.